SOX-10 expression in cutaneous myoepitheliomas and mixed tumors

Journal of Cutaneous Pathology (Impact Factor: 1.58). 12/2013; 41(4). DOI: 10.1111/cup.12279
Source: PubMed


SOX-10 can be demonstrated by immunohistochemistry in salivary gland myoepitheliomas, but its expression in cutaneous myoepitheliomas and in cutaneous mixed tumors with prominent myoepithelial cells has not been studied.
We assessed the staining pattern of SOX-10 in 5 cutaneous myoepitheliomas and 6 cutaneous mixed tumors with a prominent myoepithelial component among both the myoepithelial cells and cells lining lumens. Additionally, we examined the staining of S100, microphthalmia-associated transcription factor (MiTF) keratin cocktail, HMK903, smooth muscle actin (SMA) and epithelial membrane antigen (EMA).
SOX-10 positivity was seen in 3/5 (60%) cutaneous myoepitheliomas and in the myoepithelial cells of all cutaneous mixed tumors. SOX-10 expression on the cells lining the glandular structures in mixed tumors was variable. All myoepitheliomas and mixed tumors were positive for S100 and negative for MiTF. Pan-keratin, HMK903, smooth muscle actin (SMA) and epithelial membrane antigen (EMA) showed variable expression.
SOX-10 is a relatively reliable marker for staining cutaneous myoepitheliomas. Cutaneous myoepitheliomas are notoriously difficult to diagnose, and the addition of SOX-10 to the repertoire of stains that can label this tumor is of practical utility. These results futher support that cutaneous myoepitheliomas and cutaneous mixed tumors exist on a morphologic and immunophenotypic spectrum.

29 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: SOX genes are transcription factors with important roles in embryonic development and carcinogenesis. The SOX family of 20 genes is responsible for regulating lineage and tissue specific gene expression patterns, controlling numerous developmental processes including cell differentiation, sex determination, and organogenesis. As is the case with many genes involved in regulating development, SOX genes are frequently deregulated in cancer. In this perspective we provide a brief overview of how SOX proteins can promote or suppress cancer growth. We also present a pan-cancer analysis of aberrant SOX gene expression and highlight potential molecular mechanisms responsible for their disruption in cancer. Our analyses indicate the prominence of SOX deregulation in different cancer types and reveal potential roles for SOX genes not previously described in cancer. Finally, we summarize our recent identification of SOX15 as a candidate tumor suppressor in pancreatic cancer and propose several research avenues to pursue to further delineate the emerging role of SOX15 in development and carcinogenesis.
    Full-text · Article · Jun 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Myoepithelial neoplasms represent a heterogenous group of tumors of which classification is incomplete and evolving. Those of the soft tissues often form genetically distinct subgroups that differ from those arising within salivary glands. Soft-tissue myoepithelial tumors (including mixed tumors that show true glandular or ductal differentiation) exhibit a spectrum of different morphologic patterns, making them difficult to distinguish from a variety of other neoplasms. They have been increasingly shown to harbor genetic fusions involving EWSR1 and partner genes that are not seen in the well-characterized tumor classes involving EWSR1 translocations. We review the spectrum of soft-tissue myoepithelial tumors, discussing recent immunohistochemical and genetic findings and the differential diagnosis.
    No preview · Article · Nov 2014 · Advances in Anatomic Pathology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Context: During the last 5 to 10 years, significant progress has been made in the molecular characterization of soft tissue tumors, predominantly with the identification of recurrent translocations or amplification of certain genes in different tumor types. Alongside this, translational efforts have identified many novel and diagnostically useful immunohistochemical markers for many of these tumor types. Objective: This article reviews a select group of recently described immunohistochemical markers of particular use in the evaluation of mesenchymal neoplasms; the underlying biology of the protein product, practical utility, and limitations of each marker are discussed in detail. Data sources: Literature review, authors' research data, and personal practice experience serve as sources. Conclusions: There are many diagnostically useful immunohistochemical markers to help confirm the diagnosis of many different soft tissue tumor types, some of which have reduced the need for additional, and more costly, studies, such as fluorescence in situ hybridization. However, no one marker is 100% specific for a given tumor, and knowledge of potential pitfalls and overlap in patterns of staining among other tumor types is crucial to ensure the appropriate application of these markers in clinical practice.
    No preview · Article · Jan 2015 · Archives of pathology & laboratory medicine
Show more